ReviewEndocrine pathology2025
Reticulin Framework Assessment in Neoplastic Endocrine Pathology.
Review in Endocrine pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Validation of the Reticulin Algorithm for Adrenocortical Neoplasms: Assessing Diagnostic Accuracy Across All Age Groups and Histological Subtypes.Endocrine pathology · 2026Article
- From Tissue Architecture To Genetic Signature: Artificial intelligence-based Analysis of Reticulin Framework and Clinical Variables Predicts Molecular Cluster in Paragangliomas.Endocrine pathology · 2026Article
- Avoiding overdiagnosis of parathyroid carcinoma.Virchows Archiv : an international journal of pathology · 2026Review
- Targeting lineage-specific heterogeneity and hypovascular-fibrotic barriers may enable precision immunotherapy in pituitary neuroendocrine tumors.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The reticulin framework, composed mainly of type III collagen, is an essential structural component of biological tissues. Reticulin stains, particularly silver-based methods, enable detailed visualization of reticulin framework alterations, which have been proven to be quick, low-cost, and reliable solutions for highlighting quantitative and qualitative changes of reticulin framework and have been variably associated with neoplastic and non-neoplastic conditions. This review provides an updated overview of reticulin stain applications and reticulin framework assessment in endocrine and neuroendocrine neoplasms, including those of the pituitary, parathyroid, adrenal, and other neuroendocrine systems. In pituitary neuroendocrine tumors, reticulin framework loss serves as a distinguishing feature between normal and neoplastic adenohypophysis. Parathyroid neoplasms, including adenomas, atypical tumors, and carcinomas, exhibit varying degrees of reticulin framework disruption, which may aid in differential diagnosis. Similarly, in adrenocortical neoplasms, reticulin framework evaluation plays a crucial role in malignancy assessment, as defined in the reticulin algorithm, which incorporates reticulin framework alterations alongside three Weiss criteria: necrosis, high mitotic count (> 5/10 mm
Indexed as
Identifiers
40465053What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.